Chiesi Group Acquires KalVista Pharmaceuticals for $1.9B
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 29 2026
0mins
Should l Buy KALV?
Source: seekingalpha
- Acquisition Overview: Chiesi Group, an Italian pharmaceutical company, has agreed to acquire U.S. rare disease drug developer KalVista Pharmaceuticals for nearly $1.9 billion in an all-cash deal, with a purchase price of $27.00 per share, expected to close in Q3 2026.
- Product Integration Benefits: This acquisition will provide Chiesi with KalVista's FDA-approved oral treatment Ekterly (sebetralstat), specifically for hereditary angioedema, which generated $49 million in sales last year, enhancing Chiesi's rare immunology portfolio.
- Revenue Growth Potential: Chiesi aims to achieve €6 billion in revenue by the end of the decade, and the integration of Ekterly is expected to significantly contribute to this target, further driving the company's long-term growth strategy.
- Historic Transaction Impact: This deal marks Chiesi's largest acquisition to date, underscoring its commitment to expanding in the global pharmaceutical market while providing substantial returns to KalVista's shareholders.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy KALV?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on KALV
Wall Street analysts forecast KALV stock price to rise
9 Analyst Rating
9 Buy
0 Hold
0 Sell
Strong Buy
Current: 26.720
Low
29.00
Averages
34.38
High
39.00
Current: 26.720
Low
29.00
Averages
34.38
High
39.00
About KALV
KalVista Pharmaceuticals, Inc. is a global pharmaceutical company. It has discovered and developed EKTERLY, an oral on-demand treatment for hereditary angioedema (HAE). EKTERLY is formulated as a film-coated tablet for oral administration, with high bioavailability and selectivity for plasma kallikrein, enabling maximal dosing and a rapid decline in edema effectors that cause swelling during an HAE attack. Its clinical trials include KONFIDENT-KID, KONFIDENT-S and KONFIDENT. KONFIDENT-KID is an open-label clinical trial of sebetralstat for on-demand treatment of HAE attacks in pediatric patients. KONFIDENT-KID collects safety, pharmacokinetic and efficacy data for each patient for up to one year and features a proprietary pediatric orally disintegrating tablet formulation of sebetralstat. KONFIDENT-S study is an open-label extension trial to evaluate the long-term safety of sebetralstat for on-demand treatment of HAE attacks in adolescent and adult patients with type I or type II HAE.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Investor Rights Law Firm Investigates RE/MAX and Others
- Shareholder Rights Investigation: Halper Sadeh LLC is investigating RE/MAX Holdings, Inc. (NYSE:RMAX) regarding its sale to The Real Brokerage Inc., which involves terms of either 5.152 shares or $13.80 in cash per share, potentially limiting superior competing offers and impacting shareholder interests.
- Legal Rights Protection: The law firm encourages RE/MAX shareholders to reach out to discuss their rights and options, promising to handle matters on a contingent fee basis, ensuring shareholders' legal rights are upheld without upfront costs.
- Additional Company Investigations: Halper Sadeh LLC is also investigating KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) regarding its sale to Chiesi Group for $27.00 per share in cash, which may pose potential violations of shareholder rights.
- Global Investor Support: The firm represents investors worldwide, focusing on combating securities fraud and corporate misconduct, having successfully recovered millions for defrauded investors, highlighting its significant role in protecting investor rights.
See More
KALVISTA PHARMACEUTICALS INC: STIFEL Downgrades to Hold from Buy and Lowers Target Price to $27 from $42
Stock Rating Change: KalVista Pharmaceuticals has had its stock rating downgraded from "Buy" to "Hold" by Stifel.
Target Price Adjustment: The target price for KalVista's stock has been reduced significantly from $42 to $27.
See More
Investor Rights Law Firm Investigates Multiple Companies
- Investigation Focus: Halper Sadeh LLC is investigating companies such as XOMA Royalty Corporation, RE/MAX Holdings, Inc., and KalVista Pharmaceuticals, Inc. for potential violations of federal securities laws and breaches of fiduciary duties, which may impact shareholder rights.
- Transaction Details: XOMA is being sold to Ligand Pharmaceuticals for $39.00 per share, RE/MAX is selling for either 5.152 shares or $13.80 in cash per share to The Real Brokerage, and KalVista is being sold for $27.00 per share in cash to Chiesi Group, with terms that may limit superior competing offers.
- Shareholder Rights Protection: Halper Sadeh LLC encourages shareholders to contact them to discuss their rights and options at no cost, indicating the firm’s commitment to providing risk-free legal support for investors.
- Legal Service Commitment: The firm represents investors globally, focusing on combating securities fraud and corporate misconduct, having successfully implemented corporate reforms and recovered millions for defrauded investors, showcasing its expertise and effectiveness in protecting shareholder interests.
See More
KALVISTA PHARMACEUTICALS INC: LEERINK PARTNERS LOWERS RATING TO MARKET PERFORM FROM OUTPERFORM; INCREASES TARGET PRICE TO $27 FROM $22
Company Overview: Kalvista Pharmaceuticals is a company focused on developing treatments for diseases related to the eye and other conditions.
Market Performance: The company has seen a cut in its market performance, indicating challenges in its stock value or overall market position.
Target Price Adjustment: Analysts have raised the target price for Kalvista Pharmaceuticals from $22 to $27, reflecting a more optimistic outlook on the company's future performance.
Investment Implications: The increase in target price suggests potential investment opportunities for stakeholders, as it may indicate expected growth or recovery in the company's market standing.
See More
KalVista Pharmaceuticals Acquired by Italy's Chiesi Group
- Acquisition Boosts Stock Price: KalVista Pharmaceuticals' stock surged 38.62% to $26.67 following news that Italy's Chiesi Group will acquire the company for $27 per share in cash, indicating strong market expectations for the deal's success.
- Volume Surge: Trading volume reached 69.4 million shares, approximately 3,323% above the three-month average of 2 million shares, reflecting heightened investor interest and increased market activity surrounding the acquisition.
- Market Positioning and Product Integration: KalVista's EKTERLY, an oral therapy for hereditary angioedema affecting 1 in 50,000 people, will enhance Chiesi's portfolio of rare disease treatments, strengthening its competitive position in the market.
- Short-Term Risks and Long-Term Potential: Although KalVista was one of the most shorted stocks with a 40% short interest, Chiesi's larger international scale is expected to help the nascent treatment reach more potential patients, thereby enhancing future revenue prospects.
See More
Investor Rights Law Firm Investigates Multiple Companies for Potential Violations
- Legal Investigation Launched: Halper Sadeh LLC is investigating KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) regarding its sale to Chiesi Group for $27.00 per share, as potential violations of shareholder rights may lead to increased compensation for investors if substantiated.
- Shareholder Rights Protection: The firm is also examining TruBridge, Inc. (NASDAQ:TBRG)'s sale to Inventurus Knowledge Solutions, Inc. for $26.25 per share, encouraging shareholders to contact the firm to understand their legal rights and options, thereby safeguarding their interests.
- Merger Transaction Review: The merger between UniFirst Corporation (NYSE:UNF) and Cintas Corporation, involving $155.00 in cash and 0.7720 shares of Cintas stock per UniFirst share, may prompt Halper Sadeh LLC to seek increased consideration or other remedies to protect shareholder rights.
- Commitment to Legal Services: Halper Sadeh LLC offers risk-free legal consultations, allowing shareholders to learn about their rights and options without upfront costs, ensuring they receive due compensation in cases of potential securities fraud and corporate misconduct.
See More
Investor Rights Law Firm Investigates RE/MAX and Others
- Shareholder Rights Investigation: Halper Sadeh LLC is investigating RE/MAX Holdings, Inc. (NYSE:RMAX) regarding its sale to The Real Brokerage Inc., which involves terms of either 5.152 shares or $13.80 in cash per share, potentially limiting superior competing offers and impacting shareholder interests.
- Legal Rights Protection: The law firm encourages RE/MAX shareholders to reach out to discuss their rights and options, promising to handle matters on a contingent fee basis, ensuring shareholders' legal rights are upheld without upfront costs.
- Additional Company Investigations: Halper Sadeh LLC is also investigating KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) regarding its sale to Chiesi Group for $27.00 per share in cash, which may pose potential violations of shareholder rights.
- Global Investor Support: The firm represents investors worldwide, focusing on combating securities fraud and corporate misconduct, having successfully recovered millions for defrauded investors, highlighting its significant role in protecting investor rights.
See More
KALVISTA PHARMACEUTICALS INC: STIFEL Downgrades to Hold from Buy and Lowers Target Price to $27 from $42
Stock Rating Change: KalVista Pharmaceuticals has had its stock rating downgraded from "Buy" to "Hold" by Stifel.
Target Price Adjustment: The target price for KalVista's stock has been reduced significantly from $42 to $27.
See More
Investor Rights Law Firm Investigates Multiple Companies
- Investigation Focus: Halper Sadeh LLC is investigating companies such as XOMA Royalty Corporation, RE/MAX Holdings, Inc., and KalVista Pharmaceuticals, Inc. for potential violations of federal securities laws and breaches of fiduciary duties, which may impact shareholder rights.
- Transaction Details: XOMA is being sold to Ligand Pharmaceuticals for $39.00 per share, RE/MAX is selling for either 5.152 shares or $13.80 in cash per share to The Real Brokerage, and KalVista is being sold for $27.00 per share in cash to Chiesi Group, with terms that may limit superior competing offers.
- Shareholder Rights Protection: Halper Sadeh LLC encourages shareholders to contact them to discuss their rights and options at no cost, indicating the firm’s commitment to providing risk-free legal support for investors.
- Legal Service Commitment: The firm represents investors globally, focusing on combating securities fraud and corporate misconduct, having successfully implemented corporate reforms and recovered millions for defrauded investors, showcasing its expertise and effectiveness in protecting shareholder interests.
See More
KALVISTA PHARMACEUTICALS INC: LEERINK PARTNERS LOWERS RATING TO MARKET PERFORM FROM OUTPERFORM; INCREASES TARGET PRICE TO $27 FROM $22
Company Overview: Kalvista Pharmaceuticals is a company focused on developing treatments for diseases related to the eye and other conditions.
Market Performance: The company has seen a cut in its market performance, indicating challenges in its stock value or overall market position.
Target Price Adjustment: Analysts have raised the target price for Kalvista Pharmaceuticals from $22 to $27, reflecting a more optimistic outlook on the company's future performance.
Investment Implications: The increase in target price suggests potential investment opportunities for stakeholders, as it may indicate expected growth or recovery in the company's market standing.
See More
KalVista Pharmaceuticals Acquired by Italy's Chiesi Group
- Acquisition Boosts Stock Price: KalVista Pharmaceuticals' stock surged 38.62% to $26.67 following news that Italy's Chiesi Group will acquire the company for $27 per share in cash, indicating strong market expectations for the deal's success.
- Volume Surge: Trading volume reached 69.4 million shares, approximately 3,323% above the three-month average of 2 million shares, reflecting heightened investor interest and increased market activity surrounding the acquisition.
- Market Positioning and Product Integration: KalVista's EKTERLY, an oral therapy for hereditary angioedema affecting 1 in 50,000 people, will enhance Chiesi's portfolio of rare disease treatments, strengthening its competitive position in the market.
- Short-Term Risks and Long-Term Potential: Although KalVista was one of the most shorted stocks with a 40% short interest, Chiesi's larger international scale is expected to help the nascent treatment reach more potential patients, thereby enhancing future revenue prospects.
See More
Investor Rights Law Firm Investigates Multiple Companies for Potential Violations
- Legal Investigation Launched: Halper Sadeh LLC is investigating KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) regarding its sale to Chiesi Group for $27.00 per share, as potential violations of shareholder rights may lead to increased compensation for investors if substantiated.
- Shareholder Rights Protection: The firm is also examining TruBridge, Inc. (NASDAQ:TBRG)'s sale to Inventurus Knowledge Solutions, Inc. for $26.25 per share, encouraging shareholders to contact the firm to understand their legal rights and options, thereby safeguarding their interests.
- Merger Transaction Review: The merger between UniFirst Corporation (NYSE:UNF) and Cintas Corporation, involving $155.00 in cash and 0.7720 shares of Cintas stock per UniFirst share, may prompt Halper Sadeh LLC to seek increased consideration or other remedies to protect shareholder rights.
- Commitment to Legal Services: Halper Sadeh LLC offers risk-free legal consultations, allowing shareholders to learn about their rights and options without upfront costs, ensuring they receive due compensation in cases of potential securities fraud and corporate misconduct.
See More
